SCHEMBL6415096

SCHEMBL6415096

NN=C(c1ccc(-c2cccc(C(N)=O)c2)o1)c1nc2nonc2nc1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.38
RPS6KB1 P23443 1/20 0.38
TDO2 P48775 1/20 0.38
RPA1 P27694 1/20 0.37
MAPT P10636 3/20 0.36
ALDH1A1 P00352 1/20 0.36
BIRC5 O15392 1/20 0.36
C3AR1 Q16581 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.35
TP53 P04637 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
SLC9A1 P19634 1/20 0.35
POLB P06746 1/20 0.35
CCR2 P41597 1/20 0.35
CCR5 P51681 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
SYK P43405 2/20 0.34
DYRK1A Q13627 1/20 0.34
ABL1 P00519 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415959 0.94 BIRC5 (0.42) RPA1MAPTALDH1A1BIRC5C3AR1
SCHEMBL6416017 0.93 KDR (0.38) RPA1MAPTALDH1A1BIRC5TP53
SCHEMBL6419710 0.90 MAPT (0.40) MAPTALDH1A1BIRC5TP53SMN1; SMN2
SCHEMBL6415907 0.87 BIRC5 (0.41) MAPTALDH1A1BIRC5SLC9A1POLB
SCHEMBL6419747 0.86 BIRC5 (0.43) RPA1MAPTALDH1A1BIRC5TP53
SCHEMBL6414872 0.86 RPA1 (0.43) TDO2RPA1MAPTALDH1A1POLB
SCHEMBL6432253 0.85 RPA1 (0.44) RPA1MAPTALDH1A1C3AR1POLB
SCHEMBL6431830 0.84 BIRC5 (0.44) MAPTALDH1A1BIRC5SLC9A1POLB
SCHEMBL6434895 0.83 BIRC5 (0.45) MAPTALDH1A1BIRC5TP53SMN1; SMN2
SCHEMBL6413428 0.81 BIRC5 (0.47) MAPTALDH1A1BIRC5ABCG2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 AURKA 1279/4885RPS6KB1 654/4885TDO2 2705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.